Targeting Inflammation in Bronchiectasis

Area of Science:

• Pulmonary Medicine
• Immunology
• Microbiology

Background:

• Bronchiectasis is characterized by chronic infection, inflammation, and impaired mucociliary clearance, leading to lung injury.
• Neutrophil-driven inflammation significantly impacts disease severity, exacerbations, and quality of life in bronchiectasis.
• Recent research reveals distinct inflammatory endotypes influenced by microbial species, immune signaling, and mucosal immunity failures.

Purpose of the Study:

• To synthesize recent mechanistic and clinical insights into airway inflammation in bronchiectasis.
• To propose an integrated framework for understanding and targeting inflammation.
• To highlight the need for improved endotyping and biomarker-guided patient selection for novel therapies.

Main Methods:

• Review and synthesis of current mechanistic and clinical research on bronchiectasis inflammation.
• Analysis of emerging roles of microbial interactions, fungi, pathobionts, and the microbiome.
• Evaluation of current and emerging anti-inflammatory therapeutic strategies.

Main Results:

• Inflammatory endotypes are defined by microbial composition, immune receptor activation, and cytokine networks.
• Viral-bacterial interactions and the broader microbiome challenge the infection-only paradigm.
• Emerging anti-inflammatory strategies show promise, contrasting with mixed results from antibacterial trials.

Conclusions:

• Understanding the heterogeneity of microbiome and host immune signaling is crucial for effective treatment.
• Anti-inflammatory approaches, guided by better endotyping and biomarkers, are essential for managing bronchiectasis.
• An integrated framework is needed to effectively target airway inflammation in bronchiectasis.